Your feedback provides us with vital information that assists in the development of future educational initiatives.
Assessment of Learning Objectives

Using a scale of poor to excellent, please indicate your level of confidence in the learning objective as it relates to your knowledge, belief, or behavior, pre-program and post-program.

Question Title

* Fatty Liver Disease and NASH | Giada Sebastiani, MD

Your knowledge of the underlying mechanisms and the risk of developing liver disease and nonalcoholic steatohepatitis (NASH) in patients with diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Your knowledge of the emerging diagnostic tools and therapeutics for fatty liver disease and NASH:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Effectiveness of Speaker:

Question Title

* Additional comments:

Question Title

* Technology Update | Alanna Weisman, MD

Your knowledge of new and emerging technologies in glucose monitoring and insulin delivery for type 1 and type 2 diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Effectiveness of Speaker:

Question Title

* Additional comments:

Question Title

* Exercise and Type 1 Diabetes | Jane Yardley, PhD

Your knowledge of the effectiveness and safety of high-intensity interval training (HIIT) in patients with type 1 diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Your knowledge of the rationale and evidence of HIIT vs. continuous aerobic trainings on blood glucose level:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Your knowledge of current evidence and guidelines on continuous glucose monitoring (CGM) for the interpretation and management of blood glucose during exercise:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Effectiveness of Speaker:

Question Title

* Additional comments:

Question Title

* Update on Dyslipidemia | George Thanassoulis, MD

Your knowledge of the 2021 CCS Dyslipidemia Guidelines and key recommendations for people living with diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Effectiveness of Speaker:

Question Title

* Additional comments:

Question Title

* Remission in Type 2 Diabetes | Zubin Punthakee, MD

Your knowledge of the definition of type 2 diabetes remission:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Your knowledge of the REMIT study and implications for people with a recent diagnosis of type 2 diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Effectiveness of Speaker:

Question Title

* Additional comments:

Question Title

* Current and Future Approaches to Type 1 Diabetes: Beyond Insulin and Technology | Peter Senior, MD

Your knowledge of the latest clinical trials and data for the prevention of type 1 diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Your knowledge of emerging treatments and therapies beyond insulin for the management of patients with type 1 diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Effectiveness of Speaker:

Question Title

* Additional comments:

Question Title

* Debate: Use of SGLT2is in Hospital | Jacob A. Udell, MD and Shelley Zieroth, MD

Your knowledge of pros and cons for the use of SGLT2is in patients hospitalized with heart failure with or without diabetes:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Your knowledge of the potential outcomes associated with the use of SGLT2is during hospitalization:

  Poor Fair Good Very Good Excellent
Before
After

Question Title

* Effectiveness of Speaker - Dr. Jacob A. Udell:

Question Title

* Effectiveness of Speaker - Dr. Shelley Zieroth:

Question Title

* Additional comments:

Additional Feedback 

Question Title

* 2. From what you have learned, how will this impact / modify your practice and what will you be able to apply to your practice? What potential barriers do you anticipate and how will you overcome them?

Question Title

* Please indicate which CanMEDS roles you felt were addressed during this educational activity?

Question Title

* Sessions allocated at least 25% of the time for interaction

Question Title

* Did you perceive any sources of commercial bias in any of the sessions? If so, please explain:    

Question Title

* Did the activity comply with the Code of Ethics for parties involved in continuing medical education?

Question Title

* Were there any topics you think should have been addressed?  Any recommendations for future sessions?

Question Title

* Please share any additional comments:

Thank you!

T